Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00899587
Recruitment Status : Unknown
Verified May 2009 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : May 12, 2009
Last Update Posted : May 12, 2009
Sponsor:
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:

In this study, patients were divided into 3 group with 35 cases including: 1.oxygen 2.enalapril 3.control.

In the beginning of the study, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), and optical coherence tomography (OCT) were measured. Patients in the oxygen group were given oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month. In the enalapril group, patients were given enalapril 5 mg every night and placebo was given for the patients in third group. At the end of first month the patients' vision was checked again and at the the end of the third month the first physical examinations were performed. In the first group, arterial blood gas (ABG) was taken before and after oxygen therapy as well.


Condition or disease Intervention/treatment Phase
Diabetic Macular Ischemia Drug: enalapril Other: oxygen Drug: placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Official Title: Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: Oxygen Other: oxygen
oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month

Experimental: Enalapril Drug: enalapril
enalapril 5 mg every night

Placebo Comparator: Control Drug: placebo




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients diagnosed with diabetic macular ischemia

Exclusion Criteria:

  • HTN > 1140/90 or HTN controlled by ACE inhibitors
  • FBS > 200
  • Severe anemia, COPD, cataract, HRPDR and diffuse macular edema

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899587


Contacts
Layout table for location contacts
Contact: Masoud Soheilian, MD +982122585952 labbafi@hotmail.com

Locations
Layout table for location information
Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Masoud Soheilian, MD    +98 21 22585952    labbafi@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00899587    
Other Study ID Numbers: 8753
First Posted: May 12, 2009    Key Record Dates
Last Update Posted: May 12, 2009
Last Verified: May 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Pathologic Processes
Enalapril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents